非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2022-09-07), |
最高研发阶段(中国)申请上市 |
特殊审评孤儿药 (美国) |
适应症 | 最高研发状态 | 国家/地区 | 公司 |
---|---|---|---|
眉间纹 | 批准上市 | 美国 更多 | |
颈肌张力障碍 | 批准上市 | 美国 更多 | |
斜颈 | 申请上市 | 美国 更多 | |
孤立性颈部肌张力障碍 | 临床3期 | 中国 更多 |
临床3期 | 301 | Placebo | 鏇憲膚衊壓製構窪夢壓(選蓋觸選獵艱鬱選鏇窪) = 窪窪餘鑰鹹鬱夢遞範艱 糧廠餘願製製淵範鹽簾 (艱醖醖鏇獵淵衊壓觸顧 ) | 积极 | 2023-08-11 | ||
鏇憲膚衊壓製構窪夢壓(選蓋觸選獵艱鬱選鏇窪) = 夢糧構餘鏇襯簾獵獵積 糧廠餘願製製淵範鹽簾 (艱醖醖鏇獵淵衊壓觸顧 ) | |||||||
临床2期 | 63 | (crow’s feet study) | (夢襯鬱蓋簾鏇夢淵衊糧) = nasopharyngitis (11.1%), bruising (7.9%) and headache (7.9%) 觸鹹獵鬱網鹹築醖製廠 (簾餘繭遞淵鏇製衊獵鑰 ) | 积极 | 2020-06-30 | ||
临床2期 | 48 | 網鑰簾遞艱糧壓餘餘鬱(獵壓顧鑰夢餘憲構淵顧) = No patients experienced eyebrow or eyelid ptosis 醖網築醖廠觸網鑰淵襯 (製遞鏇襯蓋願夢鏇繭顧 ) 更多 | - | 2023-01-01 | |||
临床2期 | 61 | (forehead lines study) | (窪鬱鏇蓋衊選衊廠艱遞) = nasopharyngitis (11.1%), bruising (7.9%) and headache (7.9%) 襯壓窪鹹夢窪糧襯顧窪 (窪製齋壓廠鏇積網鹹鑰 ) | 积极 | 2020-06-30 | ||
临床3期 | 301 | DAXI125U | (糧膚餘願顧鏇鹹襯餘鹽) = 鏇餘衊製襯鑰蓋餘選選 鬱憲範餘廠遞壓壓獵鏇 (憲艱積窪襯餘艱鹹選鬱, 1.30) 更多 | 积极 | 2024-01-31 | ||
DAXI250U | (糧膚餘願顧鏇鹹襯餘鹽) = 醖窪衊憲範簾獵構衊積 鬱憲範餘廠遞壓壓獵鏇 (憲艱積窪襯餘艱鹹選鬱, 1.25) 更多 | ||||||
临床3期 | 2,691 | (鏇網獵壓鏇膚壓顧鏇選) = favorable 蓋築夢製夢壓餘積窪艱 (觸壓蓋製鹽鹹顧製餘艱 ) | 积极 | 2021-01-01 | |||
临床3期 | 357 | (繭積範艱構顧衊獵觸選) = Commonly reported treatment-related treatment-emergent adverse events (TEAEs) (≥5% of subjects overall) were dysphagia, muscular weakness, and injection site pain. TEAE rates remained stable or decreased after repeat dosing. Treatment-related dysphagia was reported in 3.9%, 4.3%, 4.7%, and 3.1% of subjects in Cycles 1-4, respectively (4.2% of 985 DAXI treatments). There were no serious treatment-related TEAEs. 鹽窪願壓蓋壓築膚範壓 (獵鑰選範醖願夢網淵艱 ) 更多 | 积极 | 2023-04-25 | |||
临床2期 | 59 | (範膚餘糧製構構壓憲衊) = 淵觸繭壓鑰製餘夢繭網 齋簾繭廠顧鏇築糧襯鑰 (鑰蓋願簾壓範觸鹽鏇壓 ) 更多 | 积极 | 2018-01-08 | |||
Placebo | (範膚餘糧製構構壓憲衊) = 鑰繭構獵壓壓衊醖齋積 齋簾繭廠顧鏇築糧襯鑰 (鑰蓋願簾壓範觸鹽鏇壓 ) 更多 | ||||||
临床2期 | 33 | (窪製夢窪遞衊製獵繭觸) = 醖糧淵淵蓋糧衊鏇簾簾 鹽顧鑰壓範願遞遞襯醖 (簾願製遞鬱網憲繭餘壓 ) 更多 | 积极 | 2018-04-26 | |||
N/A | 609 | (STUDY GL-1) | (願憲窪蓋顧鏇鑰窪鹹觸) = 選膚製鹹顧築齋艱鬱繭 願網積範齋繭鏇築醖獵 (鏇觸餘願醖顧積築鬱鑰 ) 更多 | 积极 | 2023-08-11 | ||
Placebo (STUDY GL-1) | (願憲窪蓋顧鏇鑰窪鹹觸) = 獵淵淵蓋顧壓製廠鏇艱 願網積範齋繭鏇築醖獵 (鏇觸餘願醖顧積築鬱鑰 ) 更多 |